Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Pfizer/EyeTech's Macugen will make a big impact in the age-related macular degeneration drug market.

"In December 2004, the FDA approved Macugen (pegaptanib) for use in the treatment of wet age-related macular degeneration," said Kat Lynch, analyst at Decision Resources, Inc. "Macugen is not only the first drug in its class to gain approval for age-related macular degeneration, but it is also the first agent to gain U.S. approval for the treatment of any choroidal neovascularization lesions in wet age-related macular degeneration patients."

The new Pharmacor study entitled Age-Related Macular Degeneration also finds that launches of novel drug therapies will prompt a dramatic increase in the drug-treated population, which will increase nearly sevenfold from 107,000 patients in 2003 to approximately 750,000 patients in 2013 in the major pharmaceutical markets.

About Age-Related Macular Degeneration

As a vision-threatening disease affecting an ever-growing aging population, age-related macular degeneration presents developers of innovative drug therapies with considerable potential for commercial success. Expansion of the drug-treated patient pool and increasing use of photodynamic therapy in combination with one or more emerging therapies will expand the age-related macular degeneration market from $275 million in 2003 to nearly $2.3 billion in 2013.

Wet Versus Dry

Wet age-related macular degeneration is characterized by abnormal blood vessel growth under the retina. Dry age-related macular degeneration is characterized by thinning (atrophy) of part of the retina. Currently, no therapies are available to treat dry age-related macular degeneration.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Amgen's Novel Biological Agent for Treatment of Osteoporosis Will Become a Blockbuster by 2013

View Now